GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new ...

GlaxoSmithKline has filed its new COPD triple therapy with the FDA a full 18 months early, giving it a much needed boost in its respiratory franchise. The once-daily, 'closed triple therapy ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

The company’s two established vaccines continue to boost sales for GSK’s greater vaccine portfolio, with Bexsero crossing the $1 billion milestone in 2024 and Menveo adding 387 million euros ...

Bank of New York Mellon Corp grew its position in GSK plc (NYSE:GSK – Free Report) by 2.2% during the fourth quarter, ...

GSK is betting on AI to boost innovation for its pipeline as investor concerns cloud over the company's research-and-development productivity, but a balanced approach toward regulation is ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that GSK plc (LON:GSK) is about to go ex-dividend in just ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...